• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

Charitable Planning After The Big Beautiful Bill (OBBBA) Is Different

July 14, 2025

Walmart’s Anti-Theft Crackdown: Honest Shoppers Lose Out

July 14, 2025

Is It Worth Your Time to Join a Class Action Lawsuit?

July 14, 2025
Facebook Twitter Instagram
Trending
  • Charitable Planning After The Big Beautiful Bill (OBBBA) Is Different
  • Walmart’s Anti-Theft Crackdown: Honest Shoppers Lose Out
  • Is It Worth Your Time to Join a Class Action Lawsuit?
  • 7 Tech Habits That Are Quietly Costing You More Than You Think
  • 8 Popular Savings Tips That Actually Hurt You in the Long Run
  • Why Waiting for Monthly Financial Reports Is Creating Blind Spots and Slowing Your Growth
  • How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)
  • Learn Up to 56 Languages for Just $35
Monday, July 14
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
News

Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%

News RoomBy News RoomAugust 8, 20230 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline.

The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of $31.2 billion to $31.7 billion. Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85.

Shares of Eli Lilly jumped 10% in premarket trading Tuesday.

Here’s how Eli Lilly performed, compared with Wall Street expectations, based on a survey of analysts by Refinitiv:

  • Adjusted earnings: $2.11 per share, vs. $1.98 per share expected
  • Revenue: $8.31 billion, vs. $7.58 billion expected

The company booked net income of $1.76 billion, or $1.95 per share, for the quarter. That’s up from net income of $952.5 million, or $1.05 per share, for the same period a year ago. 

Accounting for charges associated with some intangible assets and losses on securities, the company recorded adjusted income of $1.9 billion, or $2.11 per share.

The company’s $8.31 billion in sales for the quarter marked a 28% increase from the same period a year ago. 

That revenue growth was driven by sales of breast cancer pill Verzenio, which rose 57% to $926.8 million for the quarter.

Newer drugs like Mounjaro, the company’s Type 2 diabetes injection, also fueled revenue growth, posting $979.7 million in sales for the quarter. The drug was first approved in the U.S. in May 2022 and notched just $16 million in sales in the year-ago period. 

Eli Lilly said it “has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand.”

Eli Lilly also sold the rights to its emergency diabetes treatment Baqsimi to Amphastar Pharmaceuticals in April, which brought in $579 million to the topline.

Eli Lilly’s stock has been on a tear in recent months, driven in part by positive trial results for its Alzheimer’s drug, donanemab, and the company’s progress with its promising obesity drug pipeline. 

Shares of Eli Lilly are up more than 24% for the year. With a market value of roughly $431 billion, Eli Lilly is the second-largest pharmaceutical company based in the U.S. after Johnson & Johnson.

Eli Lilly will hold a conference call with investors at 9:00 am ET. 

Executives will likely share updates on the company’s upcoming pipeline launches and recent acquisitions. That includes Eli Lilly’s $1.93 billion acquisition of Versanis, a privately held obesity drug maker. 

Executives are also likely to be asked about a lawsuit filed Monday by Nektar Therapeutics accusing Eli Lilly of undermining a drug development deal established between the two companies in 2017.

This story is developing. Please check back for updates.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

RSS Feed Generator, Create RSS feeds from URL

News November 22, 2024

X CEO Linda Yaccarino addresses Musk’s ‘go f—- yourself’ comment to advertisers

News November 30, 2023

67-year-old who left the U.S. for Mexico: I’m happily retired—but I ‘really regret’ doing these 3 things in my 20s

News November 30, 2023

U.S. GDP grew at a 5.2% rate in the third quarter, even stronger than first indicated

News November 29, 2023

Americans are ‘doom spending’ — here’s why that’s a problem

News November 29, 2023

Jim Cramer’s top 10 things to watch in the stock market Tuesday

News November 28, 2023
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

Walmart’s Anti-Theft Crackdown: Honest Shoppers Lose Out

July 14, 20250 Views

Is It Worth Your Time to Join a Class Action Lawsuit?

July 14, 20250 Views

7 Tech Habits That Are Quietly Costing You More Than You Think

July 14, 20250 Views

8 Popular Savings Tips That Actually Hurt You in the Long Run

July 14, 20250 Views
Don't Miss

Why Waiting for Monthly Financial Reports Is Creating Blind Spots and Slowing Your Growth

By News RoomJuly 13, 2025

Entrepreneur We live in a time when numbers hit our inboxes faster than we can…

How I Went From Side Hustle to 7 Figures Using These 4 AI Tools (No Tech Skills Needed)

July 13, 2025

Learn Up to 56 Languages for Just $35

July 13, 2025

Entrepreneurship Is All About Innovation — and AI Can Help

July 13, 2025
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.